Precision Biosciences Inc Dossier - Source-backed chat

Precision Biosciences Inc

DTILNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.14

Intrinsic Value $11.37median of 2 methodsbased on filings through 30 Jun 2026

Market Price $6.33Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 80% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+80%)

Data confidence Sign in to view data confidence

Market Cap $174.7M

Enterprise Value $88.6M

Shares Outstanding 27.9M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Precision BioSciences is a clinical-stage gene editing company leveraging its proprietary ARCUS platform to develop potentially curative in vivo therapies. Unlike traditional CRISPR platforms, ARCUS features a smaller size and simpler structure designed for highly defined therapeutic outcomes, such as gene elimination and excision. The company's lead program, PBGENE-HBV, has demonstrated the first-ever clinical evidence of direct cccDNA elimination and inactivation in chronic hepatitis B patients, addressing a major unmet medical need that current standard-of-care therapies cannot resolve. With a second program, PBGENE-DMD, entering clinical evaluation with FDA Fast Track designation, and a robust cash runway extending through 2028, Precision is well-positioned to achieve major clinical milestones over the next 12 to 18 months.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$19.00

Mean target$29.60

High · most bullish analyst$60.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$19.00

PBGENE-HBV clinical updates show safety concerns or transient efficacy with viral rebounds in higher dose cohorts, limiting its curative potential. PBGENE-DMD experiences enrollment delays or fails to show meaningful dystrophin expression in muscle biopsies. High cash burn forces a dilutive capital raise before key milestones are achieved, depressing the stock price toward historical lows.

Base CaseCentral scenario

$29.60

Matches the consensus mean

PBGENE-HBV continues to show dose-dependent antiviral activity and cccDNA reduction, supporting progression into Part 2 expansion of the ELIMINATE-B trial. PBGENE-DMD successfully doses its first cohorts and provides initial safety and biomarker data by year-end 2026. The company maintains disciplined spending, keeping its cash runway intact through 2028, while the stock moves toward the consensus analyst target as clinical milestones are met.

Bull CaseUpside scenario

$60.00

PBGENE-HBV achieves complete, durable elimination of cccDNA and sustained HBsAg loss in Phase 1/2a trials, establishing ARCUS as the premier platform for viral genome eradication. Simultaneously, PBGENE-DMD demonstrates high levels of near full-length dystrophin expression in early cohorts, prompting accelerated regulatory discussions with the FDA. Strategic partnerships for non-core assets bring in non-dilutive upfront capital, extending the cash runway beyond 2028 and driving the stock toward the high-end analyst target.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated ARCUS platform offering unique gene elimination and excision capabilities compared to standard CRISPR technologies.
First-ever clinical evidence of therapeutic elimination and inactivation of cccDNA in chronic hepatitis B patients.
Strong financial position with $125.8 million in cash as of March 31, 2026, providing a runway through 2028 to cover key clinical milestones.
Wholly owned pipeline focused on high-value indications (HBV and DMD) with clear regulatory pathways and Fast Track designation.

Key Investment Risks

Clinical development risk inherent to early-stage gene editing therapies, including potential safety issues or lack of durable efficacy.
Dependence on a single proprietary platform (ARCUS) for the entire pipeline's success.
High operational cash burn typical of pre-commercial biotechnology companies, which may eventually require dilutive financing if partnerships do not materialize.

Thesis Invalidation Triggers

Failure of PBGENE-HBV to show durable HBsAg declines or cccDNA elimination in expanded cohorts.
Severe adverse events or safety halts in either the ELIMINATE-B or FUNCTION-DMD clinical trials.
Significant deviation from the projected cash runway leading to premature dilutive equity offerings.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.